The global cell therapy raw materials market size was estimated at USD 4.67 billion in 2024 and is expected to grow at a CAGR of 18.16% from 2025 to 2030. Innovation in the cell culture products including media, and sera, and the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders are expected to drive the market over the forecast period. Cell therapy holds immense potential in treating these conditions, and as a result, there is a growing demand for raw materials required in the production of cell-based therapies.
Increasing investments and funding in cell therapies targeting various diseases, including cancer, urinary problems, and others, would likely drive the market over the forecast period. For instance, in August 2023, NK:IO Limited raised USD 3.50 million (Euro 3.2 million) for the cell therapy targeting the treatment of solid tumor. As more companies like NK:IO pursue research and development in this area, the demand for raw materials essential for the production of cell therapies is expected to surge. Raw materials such as cell culture, media, sera, and supplements are integral components of cell therapy manufacturing. These materials are needed to cultivate and expand therapeutic cells effectively before they can be administered to patients.
The advancements in biotechnology and cell culture techniques such as three-dimensional cell culture, aseptic techniques, and cell preservation have played a pivotal role in boosting the market. These innovations have led to the development of more efficient and cost-effective manufacturing processes, which have reduced the overall production costs of cell therapies. Consequently, this has made cell-based treatments more accessible to a wider patient population, driving up the demand for raw materials.
Furthermore, the increasing number of clinical trials for cell therapy would likely offer profitable opportunities to the market, as these demand raw materials for the successful launch of the trials. Several research institutes and biopharmaceutical & pharmaceutical companies are working on the cell therapy development. For instance, in August 2023, UCART22, UCART123, and UCART20x22 are the three chimeric antigen receptor (CAR) T-cell treatments that Cellectis is now testing in three clinical trials: NATHALI-01, BALLI-01, and AMELI-01.
Moreover, regulatory agencies have been actively supporting the growth of the cell therapy industry by streamlining approval processes and providing clear guidelines. For instance, in March 2022, the U.S. FDA released two new draught guideline materials to aid sponsors who are creating cell and gene therapy (CGT) products. The first, Human Gene Therapy Products Incorporating Human Genome Editing, offers suggestions on what details, such as safety, study design, and manufacturing, should be included in IND submissions for these medicines. The second draft include the considerations for the development of CAR-T Cell products. The FDA noted that although the title expressly mentions CAR-T cell therapies, which are intended to treat cancer, these regulations also apply more to other gene-edited cell treatments, such as T cell receptor (TCR) and natural killer (NK) cell therapies. Safety, clinical study, design, manufacturing, and analytical comparability of CAR-T products are all addressed in the publication. This has instilled confidence among investors and manufacturers, encouraging them to invest in research and development activities. As a result, the market for cell therapy raw materials has expanded to meet the growing needs of industry.
The COVID-19 pandemic had a significant impact on the cell therapy raw materials industry. The outbreak disrupted supply chains and manufacturing processes, leading to shortages and delays in the production of cell-based therapies. Lockdowns and travel restrictions hindered the transportation of raw materials, causing disruptions in the availability of critical components. Moreover, many research and clinical trials related to cell therapies were temporarily halted or slowed down due to the diversion of resources towards pandemic response efforts. Despite these challenges, the pandemic also underscored the importance of cell-based therapies, leading to increased investments in the sector and accelerated regulatory approvals for some treatments. Overall, the cell therapy raw materials industry has faced both setbacks and opportunities in the wake of COVID-19, and its trajectory continues to be shaped by ongoing global health developments.
Innovation in this market is driven by the complex and highly specialized nature of raw materials required for cell-based therapies, including stem cell therapies, CAR-T cell therapies, and other regenerative treatments. For instance, there is a significant shift toward serum-free, chemically defined, and xeno-free culture media to ensure safety, consistency, and regulatory compliance.
Leading biopharmaceutical companies’ partner with raw material suppliers to co-develop specialized reagents, culture media, and growth factors tailored for specific cell therapy applications. Similarly, academic institutions and research organizations collaborate with raw material manufacturers to advance innovations in cell culture media, biomaterials, and cell expansion techniques.
The regulatory environment ensures the safety, quality, and consistency of raw materials, which are critical for manufacturing cell-based therapies. Regulatory requirements mandate that raw materials used in cell therapy manufacturing must be GMP-compliant. This drives innovation in manufacturing processes and increases the demand for GMP-grade reagents, culture media, cytokines, and growth factors.
A product expansion scenario in the cell therapy raw materials industry involves introducing new or improved products to meet the evolving demands of cell therapy development, manufacturing, and commercialization. This expansion is driven by advancements in cell therapy technologies, regulatory requirements, and the increasing need for scalable, high-quality, and cost-effective solutions.
The cell therapy raw materials industry is experiencing significant regional expansion, indicating rapid growth and increasing market presence across different geographic regions. For instance, in July 2023, Merck invested USD 24.38 million to boost cell culture media production in the U.S. It expanded the production capacity of the Lenexa facility to manufacture cell culture media.
Based on product, the market is segmented into media, sera, cell culture supplements, antibodies, reagents & buffers, and others. The cell culture supplements segment held the largest market share of 25.27% in 2024. Due to the rising demand for animal-free cell-based therapies, the segment is anticipated to grow during the forecast period. Numerous market participants are actively exploring untapped opportunities in the market through initiatives such as the development of new products & business expansion.
The media segment is expected to grow at the highest CAGR during the forecast period. This is attributed to advancements in cell therapy research and development that have driven the need for specialized media products that support the growth and expansion of therapeutic cells. Moreover, the increasing product development of media for stem cell-based therapy would likely drive segment growth over the coming years. For instance, in May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium, a chemically defined medium that improves CAR T-cell production with better consistency, process control, and faster regulatory approval
Based on the end use, the market is segmented into biopharmaceutical & pharmaceutical companies, CMOs & CROs, and others. The biopharmaceutical & pharmaceutical companies segment held the largest market share of 53.54% in 2024. These sectors have increasingly recognized the immense potential of cell therapy in revolutionizing healthcare by providing novel treatments for a wide range of diseases, including cancer, autoimmune disorders, and degenerative conditions.
As a result, they have significantly ramped up their investments in research, development, and commercialization of cell-based therapies, spurring the demand for high-quality raw materials essential for cell therapy production. For instance, in September 2023, Novo Nordisk A/S announced an investment of USD 136 million for the construction of a cell therapy manufacturing facility at Cellerator in Denmark. The manufacturing facility, which will be housed at the Technical University of Denmark (DTU), will produce cell therapies, particularly stem cell therapies, for use in preliminary clinical studies.
On the other hand, the CMOs & CROs segment is anticipated to register the fastest CAGR of over the forecast period. The escalating trend of outsourcing services to CROs and CMOs has significantly propelled the growth of this end User segment in the market. As the field of cell therapy continues to advance and gain prominence in the healthcare industry, biopharmaceutical companies are increasingly seeking specialized expertise and resources to streamline their production processes.
CROs and CMOs offer a comprehensive range of services, from research and development to manufacturing, allowing these companies to focus on their core competencies while minimizing operational costs and risks. This strategic shift towards outsourcing has created a surge in demand for raw materials essential for cell therapy production, including growth factors, culture media, among others by CMOs, & CROs, thereby fostering the expansion of the market. Moreover, as the biopharmaceutical industry continues to invest in cell therapy research and development, the demand for raw materials will persistently rise, benefiting both CMOs and CROs as key contributors to advancements in this promising field.
North America dominated the cell therapy raw materials industry with a share of 47.30% in 2024. This is attributed to the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders which has led to a growing demand for innovative cell-based therapies. These therapies offer promising treatment options that can potentially address the unmet medical needs of patients, spurring the demand for raw materials. Furthermore, the region's robust healthcare infrastructure and well-established regulatory framework have created a conducive environment for the development and commercialization of cell therapies. This has attracted investments from both government agencies and private companies, fueling research and development activities in the field.
The U.S. cell therapy raw materials market is experiencing significant growth due to the increasing demand for advanced therapies in areas like cancer treatment, autoimmune diseases, and regenerative medicine.
Europe's cell therapy raw materials market was identified as a lucrative region in this industry. The rising demand for advanced therapy medicinal products and cell biology research in Europe has shown significant development in the past few years.
The UK cell therapy raw materials market is growing rapidly, driven by the increasing adoption of cell-based therapies for treating diseases such as cancer, autoimmune disorders, and genetic conditions. Advances in regenerative medicine and personalized treatments are fueling demand for high-quality raw materials like growth factors, cytokines, and cell culture media, which are critical for the development and production of cell therapies.
The cell therapy raw materials market in Germany is experiencing significant growth, driven by the increasing demand for innovative therapies in regenerative medicine and cancer treatment.
Asia Pacific is anticipated to showcase the fastest CAGR of 18.92% during 2025-2030. The increasing prevalence of chronic diseases and degenerative disorders in the region has spurred the demand for innovative cell therapies. These therapies offer promising solutions for conditions such as cancer, cardiovascular diseases, and neurological disorders, thereby fueling the need for raw materials in their production. Moreover, the supportive regulatory environment in many Asia Pacific countries including China, India has also been instrumental in fostering the growth of the cell therapy raw materials market.
China’s cell therapy raw materials market is rapidly expanding, fueled by the country’s growing investment in biotechnology and healthcare innovation. As the demand for advanced treatments, such as gene therapies, stem cell applications, and cancer immunotherapies, increases, there is a corresponding need for high-quality raw materials like culture media, growth factors, and reagents.
Japan’s cell therapy raw materials market is experiencing significant growth, driven by the country’s strong focus on medical innovation and regenerative medicine. As the demand for advanced therapies in areas like cancer treatment, stem cell therapies, and tissue regeneration increases, there is a rising need for high-quality raw materials, including culture media, growth factors, and scaffolds.
The MEA Cell Therapy Raw Materials Market is driven by the rising demand for advanced therapies, leading to the increasing adoption of cell and gene therapies. These therapies have the potential of treating chronic diseases, including cancer, autoimmune diseases, and rare genetic disorders. Moreover, biopharma companies and CDMOs in the region are establishing facilities for cell therapy research, driving the need for high-quality raw materials like growth factors, cytokines, and culture media.
The cell therapy raw materials market in South Africa is expanding, driven by growing demand for advanced treatments in oncology and regenerative medicine. Kuwait's Cell Therapy Raw Materials Market is anticipated to grow moderately over the forecast period.
The cell therapy raw materials market in the UAE is experiencing strong growth, fueled by advancements in regenerative medicine and personalized treatments.
The market players operating in the cell therapy raw materials market are adopting product approval to increase the reach of their products in the market, improve their availability in diverse geographical areas, and expand to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.
The following are the leading companies in the cell therapy raw materials market. These companies collectively hold the largest market share and dictate industry trends.
View a comprehensive list of companies in the Cell Therapy Raw Materials Market.
In December 2024, BioCentriq signed a long-term lease for a new manufacturing facility in Princeton, NJ, which will serve as its headquarters. The USD 12M investment will enhance its capabilities in cell therapy development and production
In October 2024, Thermo Fisher Scientific established a bioprocess design center in Genome Valley, Hyderabad. This move reflects the growing demand in the market.
In June 2023, StemCyte signed a collaboration agreement with a state-of-the-art US immune cell therapy business, to provide raw materials for drug preparation in allogeneic modified cell therapy.
In June 2023, FUJIFILM Corporation launched human iPSC-derived iCell Blood-Brain Barrier Isogenic Kit. The kit replicates the human barrier between the blood and the brain and can help with drug discovery, medication development, and the study of diseases of the central nervous system.
In June 2022, OrganaBio opened a new manufacturing facility for good manufacturing practices. The facility serves as the central hub for manufacturing extensive portfolio of perinatal and adult blood-derived tissue and cells, reinforcing the company's dedication to delivering high-quality solutions for the cell therapy industry.
Report Attribute |
Details |
Market size value in 2025 |
USD 5.47 billion |
Revenue forecast in 2030 |
USD 12.59 billion |
Growth rate |
CAGR of 18.16% from 2025 to 2030 |
Base year for estimation |
2024 |
Historical data |
2018 - 2023 |
Forecast period |
2025 - 2030 |
Quantitative units |
Revenue in USD million/billion, CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Product, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Mexico, Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia, UAE; Kuwait |
Key companies profiled |
Thermo Fisher Scientific Inc.; Merck KGaA; Danaher; Sartorius Stedim Biotech Actylis.; ACROBiosystems; STEMCELL Technologies; Grifols, S.A.; Charles River Laboratories; RoosterBio, Inc.; PromoCell GmbH |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global cell therapy raw materials market on the basis of product, end use, and region.
Product Scope Outlook (Revenue, USD Million, 2018 - 2030)
Media
Sera
Cell Culture Supplements
Antibodies
Reagents & Buffers
Others
End Use Scope Outlook (Revenue, USD Million, 2018 - 2030)
Biopharmaceutical & Pharmaceutical Companies
CROs & CMOs
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
India
Japan
South Korea
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
b. Innovation in cell culture products, including media, and sera, and the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders are expected to drive the market over the forecast period.
b. The global cell therapy raw materials market size was estimated at USD 4.67 billion in 2024 and is expected to reach USD 5.47 billion in 2025.
b. The global cell therapy raw materials market is expected to grow at a compound annual growth rate of 18.16% from 2025 to 2030 to reach USD 12.59 billion by 2030.
b. Based on product, the cell culture supplements segment held the largest market share of 25.27% in 2024. This is attributed to advancements in cell therapy research and development that have driven the need for specialized supplements supporting the growth and expansion of therapeutic cells.
b. Some of the key players operating in the market are Thermo Fisher Scientific, Inc., Merck KGaA, Danaher, Sartorius Stedim Biotech, Actylis, ACROBiosystems, STEMCELLS Technologies, Grifols, S.A., Charles River Laboratories, RoosterBio, Inc., and PromoCell GmbH, among other market players.
"The quality of research they have done for us has been excellent."